[go: up one dir, main page]

MX395266B - Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis. - Google Patents

Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis.

Info

Publication number
MX395266B
MX395266B MX2018002524A MX2018002524A MX395266B MX 395266 B MX395266 B MX 395266B MX 2018002524 A MX2018002524 A MX 2018002524A MX 2018002524 A MX2018002524 A MX 2018002524A MX 395266 B MX395266 B MX 395266B
Authority
MX
Mexico
Prior art keywords
angiogenesis
fusion protein
related diseases
treating cancer
agent
Prior art date
Application number
MX2018002524A
Other languages
English (en)
Other versions
MX2018002524A (es
Inventor
Hyei Yoon Jung
Hyuk-Sang Kwon
Jae- Hoon KANG
Jong- Hee Ko
Seok Woo Yang
Yong- Sung Kim
Youngmin Lee
Original Assignee
Il Dong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Dong Pharma filed Critical Il Dong Pharma
Publication of MX2018002524A publication Critical patent/MX2018002524A/es
Publication of MX395266B publication Critical patent/MX395266B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que contiene, como un ingrediente activo, una proteína de fusión en la que un péptido penetrante de tejido y un agente de célula del factor de crecimiento endotelial antivascular (anti-VEGF) se funden, para el tratamiento de cáncer o enfermedades relacionadas a la angiogénesis. Más específicamente, la presente invención se relaciona con un uso de la proteína de fusión para el tratamiento de cáncer o enfermedades relacionadas a la angiogénesis, en donde la proteína de fusión mejora la penetrabilidad al tejido tejido de un agente de célula del factor de crecimiento endotelial antivascular y ejerce un efecto en el cáncer seleccionado, mientras que produce un excelente efecto inhibidor de la angiogénesis y exhibe un efecto terapéutico en el cáncer que muestra resistencia o inestabilidad al agente anti-VEGF.
MX2018002524A 2015-09-01 2016-09-01 Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis. MX395266B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150123878 2015-09-01
PCT/KR2016/009801 WO2017039358A1 (ko) 2015-09-01 2016-09-01 종양 투과성 펩타이드와 향-신생혈관생성 제제가 융합된 융합단백질을 유효성분으로 포함하는 암 또는 혈관신생관련 질환 예방 및 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
MX2018002524A MX2018002524A (es) 2018-11-09
MX395266B true MX395266B (es) 2025-03-25

Family

ID=58188859

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002524A MX395266B (es) 2015-09-01 2016-09-01 Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis.

Country Status (15)

Country Link
US (1) US10919947B2 (es)
EP (1) EP3345613B1 (es)
JP (1) JP6893928B2 (es)
KR (1) KR102128966B1 (es)
CN (1) CN108348575B (es)
AU (1) AU2016317882B2 (es)
BR (1) BR112018004078A2 (es)
CA (1) CA2996937C (es)
DK (1) DK3345613T5 (es)
ES (1) ES2951260T3 (es)
FI (1) FI3345613T3 (es)
MX (1) MX395266B (es)
RU (1) RU2727238C2 (es)
SI (1) SI3345613T1 (es)
WO (1) WO2017039358A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
JP7362113B2 (ja) * 2017-06-28 2023-10-17 エルジー ハウスホールド アンド ヘルスケア リミテッド 皮膚透過促進用ペプチドが結合された融合タンパク質を含む皮膚改善用化粧料組成物
JP7751357B2 (ja) * 2017-07-18 2025-10-08 イン３バイオ・リミテッド 合成タンパク質およびその治療学的用途
WO2019050326A1 (ko) * 2017-09-08 2019-03-14 아주대학교산학협력단 뉴로필린 1 (neuropilin 1, nrp1)에 특이적으로 결합하는 펩타이드를 포함하는 조절 t 세포의 활성을 억제하기 위한 조성물
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN113164544A (zh) * 2018-10-12 2021-07-23 三钰生物科技股份有限公司 双功能性融合蛋白及其用途
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN112641928A (zh) * 2019-10-11 2021-04-13 田中纯美 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
CN112522322A (zh) * 2020-12-24 2021-03-19 深圳市人民医院 一种nrp1配体的修饰技术
CN114028541A (zh) * 2021-05-21 2022-02-11 中山大学 Gdf2在制备改善肿瘤异常血管的药物中的用途
CN118613280A (zh) * 2022-01-14 2024-09-06 上海君实生物医药科技股份有限公司 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途
KR102459219B1 (ko) * 2022-03-31 2022-10-26 주식회사 셀아이콘랩 신규한 피부투과성 펩타이드, 이를 포함하는 피부 및 점막 조성물과 이의 용도
CN121127500A (zh) 2023-04-07 2025-12-12 达科纳治疗有限公司 针对激活素a受体样1型(alk1)的双特异性激动性抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
RU2008106230A (ru) * 2005-07-19 2009-08-27 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) Средства проникновения через гематоэнцефалический барьер и внутрь клеток раковой опухоли мозга и способы их использования
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA200901301A1 (ru) 2007-06-06 2010-06-30 Домантис Лимитед Полипептиды, вариабельные домены антител и антагонисты
BRPI1015424B1 (pt) * 2009-06-22 2022-01-18 Burnham Institute For Medical Research Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
EP4306123A3 (en) * 2011-12-22 2024-04-17 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US9116159B2 (en) * 2012-05-22 2015-08-25 Regeneron Pharmaceuticals, Inc. VEGF-A121 assay
JP6391676B2 (ja) * 2013-05-23 2018-09-19 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ ニューロピリンに特異的な腫瘍浸透性ペプチド及びこのペプチドが融合された融合タンパク質
KR101551306B1 (ko) * 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도

Also Published As

Publication number Publication date
EP3345613A4 (en) 2019-08-14
KR102128966B1 (ko) 2020-07-01
EP3345613B1 (en) 2023-05-10
RU2018111390A (ru) 2019-10-04
JP2018531989A (ja) 2018-11-01
MX2018002524A (es) 2018-11-09
US20180237484A1 (en) 2018-08-23
EP3345613A1 (en) 2018-07-11
WO2017039358A1 (ko) 2017-03-09
AU2016317882B2 (en) 2021-01-28
CN108348575A (zh) 2018-07-31
US10919947B2 (en) 2021-02-16
JP6893928B2 (ja) 2021-06-23
AU2016317882A1 (en) 2018-04-19
DK3345613T5 (da) 2024-09-30
DK3345613T3 (da) 2023-07-31
CA2996937A1 (en) 2017-03-09
SI3345613T1 (sl) 2023-10-30
RU2727238C2 (ru) 2020-07-21
FI3345613T3 (fi) 2023-07-28
CA2996937C (en) 2024-02-06
BR112018004078A2 (pt) 2018-12-11
ES2951260T3 (es) 2023-10-19
RU2018111390A3 (es) 2020-01-31
CN108348575B (zh) 2022-06-14
KR20170027312A (ko) 2017-03-09

Similar Documents

Publication Publication Date Title
MX395266B (es) Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis.
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
MX395142B (es) Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
MY187047A (en) Selective pyy compounds and uses thereof
EA201792047A1 (ru) Новые соединения
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201890456A1 (ru) Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
MX2017006016A (es) Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
EP3278810A4 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201690159A1 (ru) Способы и композиции для лечения рака
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
MX382919B (es) Nuevos compuestos.
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2015000618A (es) Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.
BR112018010052A2 (pt) peptídeos com propriedades antiangiogênicas, antilinfangiogênicas e antiedêmicas e formulações de nanopartícula
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis